Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 19/20 | 0.60 |
| ▸ | KDR | P35968 | 14/20 | 0.60 |
| ▸ | INSR | P06213 | 4/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CDK4 | P11802 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3963944 | 0.85 | AXL (0.82) | AXLKDRINSR | |
| SCHEMBL4243104 | 0.84 | AXL (0.75) | AXLKDRINSR | |
| SCHEMBL4993536 | 0.84 | INSR (0.68) | AXLKDRINSRCDK4 | |
| SCHEMBL3953420 | 0.83 | AXL (0.69) | AXLKDRINSR | |
| SCHEMBL4996217 | 0.81 | AXL (0.46) | AXLKDRINSRAURKA | |
| SCHEMBL1331011 | 0.80 | AXL (0.62) | AXLKDRAURKACDK4 | |
| SCHEMBL930714 | 0.79 | AXL (0.61) | AXLKDRAURKACDK4 | |
| SCHEMBL4183258 | 0.78 | AXL (0.64) | AXLKDRINSR | |
| SCHEMBL29927686 | 0.78 | AXL (0.64) | AXLKDRINSR | |
| SCHEMBL4306539 | 0.78 | AXL (0.80) | AXLKDRINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | claimed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | claimed |
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-08-25 | — | — | US | disclosed |
| US-9353126-B2 | Substituted triazoles useful as Axl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| EP-2476679-B1 | Substituted triazoles useful as AXL inhibitors | RIGEL PHARMACEUTICALS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | MIDCAP FINANCIAL TRUST | 2015-03-12 | — | — | US | disclosed |
| US-8906922-B2 | Substituted triazoles useful as AXl inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-2476679-A2 | Substituted triazoles useful as AXL inhibitors | Rigel Pharmaceuticals, Inc. (US) | 2012-07-18 | — | — | EP | disclosed |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | RIGEL PHARMACEUTICALS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166216-B2 | Substituted triazoles useful as Axl inhibitors | AXL, TYRO3, MERTK | AXL 1/4885KDR 70/4885INSR 247/4885 |
| US-20150072959-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | AXL 1/4885KDR 70/4885INSR 247/4885 |
| US-20160243085-A1 | SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS | AXL, TYRO3, MERTK | AXL 1/4885KDR 70/4885INSR 247/4885 |
| US-20080188474-A1 | e.g. 1-phenyl-N3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-1H-1,2,4-triazole-3,5-diamine; receptor protein tyrosine kinase (AXL) antagonist; antiinflammatory, anticarcinogenic , antidiabetic agent; rheumatoid arthritis, vascular disease; breast, renal, endometrial, ovarian carcinoma, or myeloid leukemia | AXL, TYRO3, FLT3 | AXL 1/4885KDR 41/4885INSR 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.